Aliases & Classifications for Choroid Disease

MalaCards integrated aliases for Choroid Disease:

Name: Choroid Disease 12 14
Choroid Diseases 42 69
Abnormality of the Choroid 29


External Ids:

Disease Ontology 12 DOID:1417
ICD10 33 H31.9 H31 H31.8
ICD9CM 35 363.9
MeSH 42 D015862
NCIt 47 C34468
SNOMED-CT 64 193431000 193480005
UMLS 69 C0008521

Summaries for Choroid Disease

MalaCards based summary : Choroid Disease, also known as choroid diseases, is related to lumbosacral plexus lesion and cystinuria. An important gene associated with Choroid Disease is CHM (CHM, Rab Escort Protein 1), and among its related pathways/superpathways are RAB geranylgeranylation and Arginine and proline metabolism. The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and testes, and related phenotypes are nervous system and pigmentation

Wikipedia : 72 The Choroid, also known as the choroidea or choroid coat, is the vascular layer of the eye, containing... more...

Related Diseases for Choroid Disease

Graphical network of the top 20 diseases related to Choroid Disease:

Diseases related to Choroid Disease

Symptoms & Phenotypes for Choroid Disease

MGI Mouse Phenotypes related to Choroid Disease:

id Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.7 CHM CNGB3 OAT POU3F4 RAB27A RBP3
2 pigmentation MP:0001186 9.26 CHM OAT RAB27A RPE65
3 vision/eye MP:0005391 9.1 CHM CNGB3 OAT RAB27A RBP3 RPE65

Drugs & Therapeutics for Choroid Disease

Drugs for Choroid Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129497-78-5
Povidone Approved Phase 4 9003-39-8
5 Povidone-iodine Approved Phase 4 25655-41-8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Ofloxacin Approved Phase 4 82419-36-1 4583
Iodine Investigational Phase 4 7553-56-2 807
Lactitol Investigational Phase 4 585-86-4 3871
14 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
15 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
18 Hormones Phase 4,Phase 2,Phase 3,Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
20 cadexomer iodine Phase 4
21 Antiemetics Phase 4,Phase 3,Phase 2
22 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
23 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
24 Autonomic Agents Phase 4,Phase 3,Phase 2
25 BB 1101 Phase 4,Phase 3,Phase 2
26 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
28 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
29 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
30 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
protease inhibitors Phase 4,Phase 3,Phase 2
33 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1
34 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Phase 1
35 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Phase 1
36 Adrenergic Agents Phase 4
37 Adrenergic alpha-1 Receptor Antagonists Phase 4
38 Adrenergic alpha-Antagonists Phase 4
39 Adrenergic Antagonists Phase 4
40 Neurotransmitter Agents Phase 4
41 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
43 Adrenocorticotropic Hormone Phase 4
44 beta-endorphin Phase 4
45 Melanocyte-Stimulating Hormones Phase 4
46 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1
47 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
48 Ophthalmic Solutions Phase 4,Phase 2
49 Tetrahydrozoline Phase 4,Phase 2
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029

Interventional clinical trials:

(show top 50) (show all 260)

id Name Status NCT ID Phase Drugs
1 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
2 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
3 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
4 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
5 The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
6 Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab Completed NCT00417703 Phase 4
7 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
8 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
9 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed NCT01006538 Phase 4 Ranibizumab
10 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
11 Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. Completed NCT01831947 Phase 4
12 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
13 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
14 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
15 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Completed NCT00645697 Phase 4
16 Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration Completed NCT01628354 Phase 4 Ranibizumab
17 Evaluation of Dosing Interval of Higher Doses of Ranibizumab Completed NCT00533520 Phase 4 ranibizumab
18 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
19 PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization Completed NCT00358345 Phase 4
20 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4 ranibizumab
21 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Recruiting NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
22 Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Recruiting NCT02320474 Phase 4 Aflibercept
23 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
24 A Study Of Early Markers Of Choroidal Neovascularization Terminated NCT00902785 Phase 4
25 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Terminated NCT00327470 Phase 4 Pegaptanib Sodium 0.3 mg
26 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4
27 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
28 Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Unknown status NCT00344617 Phase 3 Bevacizumab (tradename: Avastin)
29 Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks Unknown status NCT00599820 Phase 3 Intravitreal Bevacizumab
30 A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration Unknown status NCT00454389 Phase 3 ranibizumab
31 Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Unknown status NCT00157976 Phase 3 Photrex (rostaporfin)
32 A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV Unknown status NCT01809223 Phase 3 conbercept, Fixed;conbercept, PRN
33 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
34 Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization Unknown status NCT00930189 Phase 2, Phase 3 intravitreal injection of ranibizumab;intravitreal injection of triamcinolone
35 TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration Unknown status NCT00260403 Phase 2, Phase 3
36 Macular Photocoagulation Study (MPS) Unknown status NCT00000158 Phase 3
37 To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis Unknown status NCT00372294 Phase 3 pyrimethamine-sulfadiazine + prednisolone;Clindamycin+Dexamethasone
38 Avastin for CNV Secondary to Pattern Dystrophy Unknown status NCT00391144 Phase 2, Phase 3
39 Efficacy of Retreatments With Intravitreal Bevacizumab Unknown status NCT00406744 Phase 3 Intravitreal injection of Bevacizumab
40 Intravitreal Bevacizumab for Inflammatory Neovascular Membranes Completed NCT00407121 Phase 3 Bevacizumab
41 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
42 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
43 Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Completed NCT01840410 Phase 3 Ranibizumab
44 Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment Completed NCT00417833 Phase 2, Phase 3 Intravitreal Bevacizumab
45 Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV) Completed NCT00370786 Phase 3 bevacizumab
46 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
47 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin
48 VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV) Completed NCT01249664 Phase 3
49 Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia Completed NCT00967850 Phase 3 Intravitreal Injection;Photodynamic Therapy (Visudyne)
50 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed NCT01908816 Phase 3 ranibizumab

Search NIH Clinical Center for Choroid Disease

Cochrane evidence based reviews: choroid diseases

Genetic Tests for Choroid Disease

Genetic tests related to Choroid Disease:

id Genetic test Affiliating Genes
1 Abnormality of the Choroid 29

Anatomical Context for Choroid Disease

MalaCards organs/tissues related to Choroid Disease:

Eye, Retina, Testes, Endothelial, Thyroid, Brain, Bone

Publications for Choroid Disease

Articles related to Choroid Disease:

id Title Authors Year

Variations for Choroid Disease

Expression for Choroid Disease

Search GEO for disease gene expression data for Choroid Disease.

Pathways for Choroid Disease

GO Terms for Choroid Disease

Cellular components related to Choroid Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 photoreceptor outer segment GO:0001750 8.62 CNGB3 RAB27A

Biological processes related to Choroid Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 retinoid metabolic process GO:0001523 9.26 RBP3 RPE65
2 cellular amino acid biosynthetic process GO:0008652 9.16 OAT PYCR1
3 visual perception GO:0007601 9.02 CHM CNGB3 OAT RBP3 RPE65
4 L-proline biosynthetic process GO:0055129 8.96 OAT PYCR1

Sources for Choroid Disease

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....